Community Research Initiative (CRI) is an independent, nonprofit, community-based organization in New England dedicated to HIV and hepatitis C clinical research, treatment education, and financial assistance for approved HIV drug treatments and health insurance coverage.
This past month offered exciting news for people living with hepatitis C (HCV), thanks to your support of CRI's research. Gilead's all-oral single-tablet treatment for HCV, known as Harvoni, was recently approved by the FDA. The approval is supported by data from three Phase III studies, including the ION-3 trial, for which CRI was the enrolling site in Massachusetts. During ION-3, as many as 95% of participants were cured of HCV. Follow the link to read more about the ION-3 trial and other clinical trials at CRI.
HDAP staff, in collaboration with the Office of HIV/AIDS (OHA) of the Massachusetts Department of Public Health, have recently conducted two webinars to provide information on HDAP and the ACA, navigating the new MA Health Connector, and on special considerations for clients with HIV and their case managers. Click "Read More" to find out how to view these webinars.
Registration for Harbor to the Bay Ride 13 is now open! Join the fun and camaraderie while making an incredible difference on Saturday, September 19, 2015. Register at www.harbortothebay.org with Team CRI, and don't forget to name Community Research Initiative as your beneficiary. CRI conducts clinical research because of the people who benefit from it, and our work is only possible with the help of the riders, crew members, donors, volunteers, and people like you. Thank you!